Cidara Therapeutics, Inc. CDTX
We take great care to ensure that the data presented and summarized in this overview for Cidara Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDTX
View all-
Bvf Inc San Francisco, CA6.86MShares$85.8 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$41.9 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.8MShares$22.5 Million0.0% of portfolio
-
Alethea Capital Management, LLC San Diego, CA1.63MShares$20.4 Million1.48% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.55MShares$19.3 Million0.08% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.25MShares$15.6 Million0.0% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA1.13MShares$14.2 Million0.36% of portfolio
-
Black Rock Inc. New York, NY938KShares$11.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA806KShares$10.1 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY635KShares$7.94 Million0.0% of portfolio
Latest Institutional Activity in CDTX
Top Purchases
Top Sells
About CDTX
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Insider Transactions at CDTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
128,750
+21.3%
|
-
|
|
Mar 15
2024
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
111,250
+23.12%
|
-
|
|
Mar 15
2024
|
Preetam Shah CFO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
108,750
+24.45%
|
-
|
|
Mar 15
2024
|
Shane Ward COO & CLO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+27.35%
|
-
|
|
Mar 11
2024
|
Preetam Shah CFO & CBO |
SELL
Open market or private sale
|
Direct |
18,931
-7.69%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Shane Ward COO & CLO |
SELL
Open market or private sale
|
Direct |
20,473
-9.34%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,662
-5.62%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
21,029
-7.52%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Jeffrey Stein President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
56,692
-4.68%
|
$0
$0.69 P/Share
|
|
Sep 11
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
18,469
-6.28%
|
$0
$0.95 P/Share
|
|
Sep 11
2023
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,793
-4.91%
|
$0
$0.95 P/Share
|
|
Aug 14
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+3.29%
|
$0
$0.97 P/Share
|
|
Aug 08
2023
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Indirect |
50,000
+13.1%
|
$0
$0.96 P/Share
|
|
Mar 27
2023
|
Jeffrey Stein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
271,750
+18.43%
|
-
|
|
Mar 27
2023
|
Shane Ward COO & CLO |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+37.49%
|
-
|
|
Mar 27
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+24.31%
|
-
|
|
Mar 27
2023
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+19.21%
|
-
|
|
Mar 27
2023
|
Preetam Shah CFO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+27.43%
|
-
|
|
Mar 27
2023
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Indirect |
50,000
+15.08%
|
$50,000
$1.04 P/Share
|
|
Mar 13
2023
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,203
-2.44%
|
$7,203
$1.53 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 469K shares |
|---|---|
| Open market or private purchase | 60K shares |
| Open market or private sale | 118K shares |
|---|---|
| Payment of exercise price or tax liability | 56.7K shares |